The cost of antiretroviral therapy in Haiti

Cost Effectiveness and Resource Allocation

Volumn 6, Issue , 2008, Pages

  Koenig, Serena P ^a   Riviere, Cynthia ^b   Leger, Paul ^b   Severe, Patrice ^b   Atwood, Sidney ^a   Fitzgerald, Daniel W ^b,c   Pape, Jean W ^b,c   Schackman, Bruce R ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Adolescent Medicine   (Haïti)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GENERIC DRUG; LAMIVUDINE; NEVIRAPINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HAITI; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PATIENT REFERRAL; RESOURCE ALLOCATION; SURVIVAL RATE; TELEPHONE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URBAN AREA;

EID: 41549124935     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-6-3     Document Type: Article

References (32)

1. Declaration of Commitment on HIV/AIDS: Five Years Later. Report of the Secretary-General, United Nations Assembly, 60th Session. 2006
2. World Health Organization. Progress on Global Access to HIV Antiretroviral Therapy: An update on "3 by 5". Geneva, Switzerland: World Health Organization, 2005. 2005
3. Coetzee D Hildebrand K Boulle A Maartens G Louis F Labatala V Reuter H Ntwana N Goemaere E Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa AIDS 2004, 18(6):887-895 10.1097/ 00002030-200404090-00006 15060436
4. Farmer P Leandre F Mukherjee JS Claude M Nevil P Smith-Fawzi MC Koenig SP Castro A Becerra MC Sachs J Attaran A Kim JY Community-based approaches to HIV treatment in resource-poor settings Lancet 2001, 358(9279):404-409 10.1016/S0140-6736(01)05550-7 11502340
5. Laurent C Diakhate N Gueye NF Toure MA Sow PS Faye MA Gueye M Laniece I Toure Kane C Liegeois F Vergne L Mboup S Badiane S Ndoye I Delaporte E The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study Aids 2002, 16(10):1363-1370 10.1097/00002030-200207050-00008 12131213
6. Severe P Leger P Charles M Noel F Bonhomme G Bois G George E Kenel-Pierre S Wright PF Gulick R Johnson WD Jr. Pape JW Fitzgerald DW Antiretroviral therapy in a thousand patients with AIDS in Haiti N Engl J Med 2005, 353(22):2325-2334 10.1056/NEJMoa051908 16319381
7. Wools-Kaloustian K Kimaiyo S Diero L Siika A Sidle J Yiannoutsos CT Musick B Einterz R Fife KH Tierney WM Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya AIDS 2006, 20(1):41-48 10.1097/ 01.aids.0000196177.65551.ea 16327318
8. Badri M Maartens G Mandalia S Bekker LG Penrod JR Platt RW Wood R Beck EJ Cost-effectiveness of highly active antiretroviral therapy in South Africa PLoS Med 2006, 3(1):e4 1298940 16318413 10.1371/ journal.pmed.0030004
9. Bautista SA Costing of HIV/AIDS treatment in Mexico Bethesda, MD, Partners for Health Reform-plus Project 2003
10. Harling G Wood R The Evolving Cost of HIV in South Africa: Changes in Health Care Cost With Duration on Antiretroviral Therapy for Public Sector Patients J Acquir Immune Defic Syndr 2007 17496562
11. Kitajima T Kobayashi Y Chaipah W Sato H Chadbunchachai W Thuennadee R Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand Aids 2003, 17(16):2375-2381 10.1097/00002030-200311070-00013 14571190
12. Kombe G The human and financial resource requirements for scaling up HIV/ AIDS services in Ethiopia Bethesda, MD, Partners for Health Reform-plus, Abt Associates 2005 16334960
13. Kombe G Galaty D Nwagbara C Scaling up antiretroviral treatment in the public sector in Nigeria: A comprehensive analysis of resource requirements Bethesda, MD, Partners for Health Reform-plus, Abt Associates 2004
14. Kombe G Smith O The costs of anti-retroviral treatment in Zambia Bethesda, MD, Partners for Health Reform-Plus, Abt Associates 2003
15. World Bank. Haiti at a Glance. 2005
16. Ministere de la Sante Publique et de la Population; Institut Haitien de l' Enfance, Centres GHESKIO, and Centers for Disease Control and Prevention. Etude de Sero Surveillance par Methode Sentinelle de la Prevalence du VIH, de la Syphilis, de l'Hepatite B chez les femmes enceintes en Haiti 2003/2004. Haiti, 2004. 2004
17. UNAIDS Report on the Global AIDS Epidemic 2006
18. Pape JW Liautaud B Thomas F Mathurin JR St Amand MM Boncy M Pean V Pamphile M Laroche AC Johnson WD Jr. Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti N Engl J Med 1983, 309(16):945-950 6621622
19. Drummond MF Sculpher MJ Torrance GW O'Brien BJ Stoddart GL Methods for the Economic Evaluation of Health Care Programmes Oxford, United Kingdom, Oxford University Press Third 2005
20. Glick R Economic Evaluation in Clinical Trials Oxford, Oxford University Press 2007
21. Chen RY Accortt NA Westfall AO Mugavero MJ Raper JL Cloud GA Stone BK Carter J Call S Pisu M Allison J Saag MS Distribution of health care expenditures for HIV-infected patients Clin Infect Dis 2006, 42(7):1003-1010 10.1086/500453 16511767
22. Schackman BR Gebo KA Walensky RP Losina E Muccio T Sax PE Weinstein MC Seage GR 3rd Moore RD Freedberg KA The lifetime cost of current human immunodeficiency virus care in the United States Med Care 2006, 44(11):990-997 10.1097/01.mlr.0000228021.89490.2a 17063130
23. Nuesch R Srasuebkul P Ananworanich J Ruxrungtham K Phanuphak P Duncombe C Monitoring the toxicity of antiretroviral therapy in resource limited settings: A prospective clinical trial cohort in Thailand J Antimicrob Chemother 2006, 58(3):637-644 10.1093/jac/dkl313 16895939
24. Moore D Mermin, J., Awor, A., Yip, B., Hogg, R., Montaner, J. Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes 2006, 43(4):436-439 10.1097/01.qai.0000243105.80393.42 17019367
25. Tehe A Maurice, C., Hanson, D.L., Borget, M.Y., Abiola, N., Maran, M., Yavo, D., Tomasik, Z., Boni, J., Schupbach, J., Nkengasong, J.N. Quantification of HIV-1 p24 by a highly improved ELISA: An alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Cote d'Ivoire Journal of Clinical Virology 2006, 37(3):199-205 10.1016/ j.jcv.2006.08.005 16973409
26. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a public health approach. Geneva: World Health Organization. 2006
27. Farmer P Political violence and public health in Haiti N Engl J Med 2004, 350(15):1483-1486 10.1056/NEJMp048081 15071121
28. Mangili A Murman DH Zampini AM Wanke CA Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort Clin Infect Dis 2006, 42(6):836-842 10.1086/500398 16477562
29. Beck EJ Miners AH Tolley K The cost of HIV treatment and care. A global review Pharmacoeconomics 2001, 19(1):13-39 10.2165/ 00019053-200119010-00002 11252543
30. Yazdanpanah Y Goldie SJ Losina E Weinstein MC Lebrun T Paltiel AD Seage GR 3rd Leblanc G Ajana F Kimmel AD Zhang H Salamon R Mouton Y Freedberg KA Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy Antivir Ther 2002, 7(4):257-266 12553480
31. Harries AD Hargreaves NJ Chimzizi R Salaniponi FM Highly active antiretroviral therapy and tuberculosis control in Africa: Synergies and potential Bull World Health Organ 2002, 80(6):464-469 12132003
32. Reid A Scano F Getahun H Williams B Dye C Nunn P De Cock KM Hankins C Miller B Castro KG Raviglione MC Towards universal access to HIV prevention, treatment, care, and support: The role of tuberculosis/HIV collaboration Lancet Infect Dis 2006, 6(8):483-495 10.1016/ S1473-3099(06)70549-7 16870527